Growth in this market is driven mainly by high incidence of nerve injuries, the growing prevalence of neurological disorders, and rising government support for neurologic disorder research.
The global Nerve Repair and Regeneration Market size is projected to reach USD 9.7 billion by 2025 from USD 6.3 billion in 2020, growing at a CAGR of 9.1% from 2020 to 2025. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=883 Market Segmentation: - By product, the nerve repair market is segmented into neurostimulation and neuromodulation devices and biomaterials. The neurostimulation and neuromodulation devices segment is segment is expected to grow at the highest growth rate during the forecast period. The large market share of this segment is driven mainly by rising government expenditure for neurologic disorders, and favorable reimbursement. Based on the neurostimulation and neuromodulation application, the nerve regeneration market is segmented the neurostimulation and neuromodulation devices market is segmented into internal neurostimulation and neuromodulation applications and external neurostimulation and neuromodulation applications. The internal neurostimulation and neuromodulation segment is estimated to register the highest CAGR during the forecast period. Based on application, the biomaterials market is segmented into direct nerve repair/neurorrhaphy, nerve grafting, and stem cell therapy. In 2019, the direct nerve repair segment accounted for the largest share of the market. Recent Developments: -
Regional Analysis: - The nerve repair market is segmented into five major regions, namely, Europe, North America, the Asia Pacific, Latin America, and Middle East & Africa. In 2019, North America accounted for the largest share of the nerve repair and regeneration industry, followed by Europe. Request for Sample Pages : - https://www.marketsandmarkets.com/requestsampleNew.asp?id=883 Top Key Players: - Some of the major players operating in the global nerve repair market include Medtronic, PLC. (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), AxoGen, Inc. (US), Baxter International, Inc. (US), LivaNova, PLC. (UK), Integra LifeSciences (US), Polyganics (Netherlands), NeuroPace, Inc. (US), Soterix Medical, Inc. (US), Nevro Corp (US), Synapse Biomedical, Inc. (US), Aleva Neurotherapeutics (Switzerland), Collagen Matrix, Inc. (US), KeriMedical (Switzerland), BioWave Corporation (US), NeuroSigma (US), tVNS Technologies GmbH(Germany), and GiMer Medical (Taiwan).
0 Comments
The growth of the global albumin & creatinine tests market is driven by factors such as the growing prevalence of kidney disorders, the rising adoption of POC diagnostics, and the increasing prevalence of chronic conditions.
The report Albumin & Creatinine Tests Market is projected to reach USD 2,103 million by 2025 from USD 987 million in 2020, at a CAGR of 16.3%. Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=156696568 The dipsticks & kits products segment accounted for the largest share of the albumin & creatinine tests market, by product segment, in 2019 Based on product, the albumin & creatinine tests market is segmented into dipsticks & kits, analyzers, cartridges, and reagents & other consumables. In 2019, the dipsticks & kits segment accounted for the largest share in this market. The frequent purchase of these products compared to instruments like analyzers and cartridges and the increasing use of kit-based rapid techniques for albumin & creatinine tests drive market growth. Urine Tests segment to register the highest growth rate during the forecast period Based on type, the albumin & creatinine tests market is segmented into urine tests and blood & serum creatinine tests. In 2019, urine tests accounted for the largest share in this market. Factors such as the rapid growth in the diagnostics segment and the increasing demand for rapid and easy-to-use urine tests drive the growth of this segment. North America is the largest regional market for albumin & creatinine tests market The global albumin & creatinine tests market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America accounted for the largest share in the global albumin & creatinine tests market. The large share of this regional segment can primarily be attributed to the growth in demand for rapid urine tests, increasing prevalence of chronic conditions leading to various kidney diseases, rising government initiatives, and growing geriatric population. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=156696568 Top Key Players:- The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Roche Diagnostics (Switzerland), PromoCell GmbH (Germany), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics (US), Randox Laboratories (UK), FUJIFILM Wako Pure Chemical Corporation (Japan), Abbexa Ltd. (UK), ACON Laboratories, Inc. (US), Arbor Assays Inc. (US), ARKRAY Global Business Inc. (Japan), Aviva Systems Biology (US), Axxora, LLC (UK), BioAssay Systems (US), Nova Biomedical (US), Quantimetrix Corporation (US), RayBiotech Inc. (US), Sekisui Diagnostics PEI Inc. (US), Teco Diagnostics (US), Tulip Diagnostics (India), ulti med Products GmbH (Germany), and URIT Medical Electronic Co., Ltd. (China). The growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are expected to restrain market growth to a certain extent.
The report Cardiac Marker Testing Market size is estimated to be USD 3.6 billion in 2020 and projected to reach USD 5.5 billion by 2025, at a CAGR of 8.9 %. Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64885447 The cardiac marker testing market includes major Tier I and II suppliers like Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US). These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. The cardiac marker testing market is also faced a period of short-term negative growth, which can be attributed to factors such as a greater than 50% drop in the number of patients with cardiovascular conditions and those diagnosed with myocardial infarction. All areas of cardiology service provision sustained significant reductions, which included outpatient clinics, investigations, procedures, and cardiology community services such as cardiac rehabilitation. Wide use of reagents and kits in all basic diagnostic activities in laboratories, academic institutes, and POC settings is expected to result in the segment occupying the majority of the cardiac marker testing market share Growing number of cardiac marker testing procedures, accessibility to a wide range of cardiac biomarker reagents and kits, and the growing demand for reliable, specific, and faster detection of cardiovascular diseases at an early stage are the key growth factors for this segment. Troponin I and T estimated to be the fastest-growing market Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market. The large share of this segment can be attributed high sensitivity and specificity, long elevation times, and rapid prediction of outcome or mortality. North America is estimated to be the largest market due increasing incidence of cardiovascular diseases, growing public and private investments, NIH support for the development of novel cardiac biomarkers, and the rising geriatric population. Asia Pacific likely to emerge as the largest cardiac marker testing market, globally Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period. The Asia Pacific market is driven due increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas) in Asia Pacific countries. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=64885447 Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US) are the key players in the global cardiac marker testing market. Factors such as the growing prevalence of target diseases, the favorable reimbursement scenario in major markets, and advancements in technologies & designs of electronic drug delivery systems are driving the growth of the electronic drug delivery systems market during the forecast period. However, emerging economies such as China, India, Russia, and Brazil offer significant growth opportunities for players in the electronic drug delivery market.
The report Electronic Drug Delivery Systems Market is projected to grow at a CAGR of 8.7% during the forecast period to reach USD 11.9 billion by 2024 from USD 7.8 billion in 2019. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=165758442 The electronic wearable infusion pumps segment accounted for the largest share of the electronic drug delivery systems market in 2018. This is primarily due to the rising prevalence of diabetes and the increasing availability of commercial infusion pumps for diabetes treatment. However, the high cost of electronic drug delivery devices, high acceptance of conventional devices, and lack of reimbursement for electronic drug delivery devices in developing countries could restrain the growth of this segment. The diabetes segment accounted for the largest share in 2018. This is primarily due to the high prevalence of diabetes across the globe and the greater availability of electronic drug delivery devices, such as insulin pumps and injection pens, for diabetes in comparison to other therapeutic areas. For instance, according to the International Diabetes Federation, in 2017, almost 425 million people were suffering from diabetes worldwide; this is expected to increase to 629 million by 2045. In 2018, North America dominated the electronic drug delivery systems market, followed by Europe. High burden of target diseases, favorable reimbursement scenario, and the presence of major market players in this region are the factors propelling the growth of the market. For instance, in April 2018, AstraZeneca (UK) received OTC clearance for its SmartTouch for Symbicort (an electronic inhaler) and launched this product in the US market. Similarly, in December 2017, Companion Medical (US), launched InPen (an electronic injection pen) in the US. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=165758442 Top Key Players:- The prominent players in the electronic drug delivery systems market are Insulet Corporation (US), Bayer AG (Germany), Medtronic (Ireland), Novo Nordisk A/S (Denmark), Companion Medical (US), F.Hoffmann-La Roche Ltd (Switzerland), United Therapeutics Corporation (US), AstraZeneca (UK), Tandem Diabetes Care (US), Merck Group (Germany), and Amgen (US). Growth in this "Ventilators Market by Mobility (Intensive Care, Portable), Type, Mode (Volume, Pressure, Combined), Interface (Invasive, Non-invasive), End-User (Hospital, Home Care, ACC, Emergency Medical Services) Covid-19 Impact - Global Forecast to 2025" is driven by the outbreak of the covid-19 pandemic, high prevalence of respiratory diseases, rapid growth in the geriatric population, increasing number of preterm births, and the rising number of ICU beds.
Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11018337 Based on mobility, the market for ventilators is segmented into intensive care ventilators and portable/transportable ventilators. The intensive care ventilators segmented is estimated to be USD 5.5 billion in 2020. It is expected to grow at AGR of 535.4% from 2019 to 2020.The intensive care ventilators segment is projected to witness the highest growth in the ventilators market during the forecast period. Growth in this segment is attributed due to the rising number of intensive care beds equipped with ventilators. The increasing ICU admission due to COVID-19 and readmissions in developed countries coupled with appropriate reimbursement is also responsible for the growth of the ICU ventilators segment. The ICU ventilators segment is further sub-segmented into high-end ICU ventilators, mid-end ICU ventilators, and basic ICU ventilators. Based on type, the market for ventilators is segmented into adult/pediatric ventilators and neonatal/infant ventilators. The adult/pediatric ventilators segment accounted for the largest share of the market in 2019. The large share of this segment is largely driven by the large adult population suffering from COVID-19, chronic diseases such as COPD & asthma, the high prevalence of smoking, and the rising geriatric population. Based on the interface, the market for ventilators is segmented into invasive ventilation and non-invasive ventilation segment. The invasive ventilation segment is projected to witness the highest growth in the ventilators market during the forecast period. Growth in the invasive ventilation market can be attributed to increasing severity in COVID-19 patients and the rising prevalence of respiratory diseases, neurological diseases, and sleeping disorders. Based on the mode of ventilation, the ventilators market is segmented into volume-mode ventilation, pressure-mode ventilation, combined-mode ventilation, and other modes. The combined-mode ventilation segment accounted for the largest share of the ventilators market. The large share of the segment is attributed to its advantages over conventional pressure-mode ventilation and volume-mode ventilation. The ability of combined-mode ventilation to provide both modes of ventilation makes it a desirable product in the ventilators market On the basis of end-user, the ventilators market is segmented into hospitals and clinics, home care, ambulatory care center, and emergency medical services. The emergency medical services segment is projected to witness the highest growth in the ventilators market during the forecast period. Growth in this segment is attributed to the high incidence of trauma injuries, such as road accidents and falls, sports injuries, and criminal injuries. Request for Sample Pages : - https://www.marketsandmarkets.com/requestsampleNew.asp?id=11018337 North America is expected to account for the largest share of the ventilators market in 2019, followed by Europe. The prominent players in the ventilators market are Philips Healthcare (Netherlands), ResMed Inc. (US), Medtronic plc (Ireland), Fisher & Paykel Healthcare Corporation Limited (New Zealand), Drägerwerk AG & CO. KGAA (Germany), Nihon Kohden Corporation (Japan), Getinge AB (Sweden), Asahi Kasei Corporation (Japan), Air Liquide (France), Vyaire Medical, Inc. (US), GE Healthcare (US), Hamilton Medical (Switzerland), Smiths Group plc (UK), Allied Healthcare Products, Inc. (US). The heavy burden of cervical cancer, rapidly growing geriatric population, and technological advancements in colposcopy are the key factors driving the growth of this market.
The Colposcopy Market is expected to reach USD 740.1 Million by 2023 from USD 532.6 Million in 2018, at a CAGR of 6.8%. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210884594 Optical colposcopes are estimated to account for the largest share of the colposcopy market in 2018 The colposcopy market is segmented on the basis of instrument type into optical colposcopes and digital colposcopes. In 2018, the optical colposcope segment is expected to account for the largest share of the colposcopy market. The large share of this segment can be attributed to advantages such as easy installation and low cost of these instruments. The portable colposcopes are expected to account for the largest share of the global colposcopy market On the basis of instrument portability, the market is segmented into portable, fixed, and handheld colposcopes. The portable colposcopes segment is expected to account for the largest share of the market in 2018 and it is also expected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to the advantages portable colposcopes offer, which include ease of installation and movement within medical settings, better result reproducibility, and the ability to produce high-definition images, and stable cervix examinations. North America is expected to command the largest share of the market during the forecast period. Based on region, the colposcopy market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to dominate the colposcopy market in 2018 and this trend is likely to continue during the forecast period. The large share of this segment can primarily be attributed to the high burden of cervical cancer, availability of technologically advanced screening tools, the presence of major players in this region, and the presence of quality healthcare infrastructure. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=210884594 Key players in the Colposcopy market include DySIS (US), CooperSurgical (US), Atmos (Germany), Olympus (Japan), Karl Kaps (Germany), McKesson (US), Danaher (US), and Carl Zeiss (Germany). High prevalence of cancer, growing demand for digital pathology, and increasing healthcare expenditure are the major factors driving the growth of this market.
The report Microtome Market is expected to grow from USD 129 million in 2019 to reach USD 177 million by 2024, at a CAGR of 6.5%. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=230495411 Manual microtomes accounted for the largest share of the microtomes market, by technology, in 2018 Microtomes operate on different technologies, including manual, semi-automated, and fully automated. Manual microtomes segment accounted for the largest market share in 2018. Manual microtomes are cost-effective and are easier to use as compared to automatic and semi-automatic modules. These factors are supporting their adoption in the market, and the trend is anticipated to continue over the forecast period. Hospital laboratories end-user segment to grow at the highest CAGR during the forecast period Clinical laboratories and hospital laboratories are the main end-users of microtomes, among others. In 2018, the hospital laboratories segment accounted for the largest market share and was expected to grow at the highest CAGR during the forecast period. The large share of the hospital laboratories segment is attributed to the increasing number of patient visits to hospitals, rising number of in-house clinical diagnostic procedures performed in hospitals, growing awareness regarding early diagnosis, and the availability of reimbursements in developed markets for clinical tests performed in hospitals. North America was the largest regional market for microtomes in 2018 By region, the microtomes market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America accounted for the largest market share, followed by Europe. The easy accessibility to advanced technologies, growing opportunities for advanced cancer diagnostic testing and screening, favorable reimbursement scenario for anatomic pathology diagnostic tests, increasing healthcare expenditure, and the presence of high-quality infrastructure for hospitals and clinical laboratories in the region are the major factors driving the growth of the microtomes market in North America. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=230495411 Top Key Players:- The prominent players operating in the microtomes market include Thermo Fisher Scientific (US), Danaher Corporation (US), Sakura Finetek (Japan), SLEE Medical GmbH (Germany), MEDITE GmbH (Germany), Histo-Line Laboratories (Italy), Amos Scientific (Australia), RMC Boeckeler (US), Diapath S.p.A. (Italy), and Jinhua YIDI Medical Appliance (China). Increasing government funding for cell-based research and the rising incidence of chronic and infectious diseases are the major factors driving the growth of this market.
The Cell Analysis Market is expected to reach USD 22.7 billion by 2024 from USD 16.0 billion in 2019, at a CAGR of 7.2%. from 2019 to 2024 Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157543946 Market Segmentation:- Based on product, the cell analysis market is broadly categorized into microscopes, flow cytometry products, spectrophotometers, qPCR products, cell counters, cell microarrays, high-content screening (HCS) systems, and other products. The flow cytometry products segment accounted for the largest market share in 2018. The large share of this segment is primarily attributed to technological advancements, the increasing adoption of flow cytometry techniques in research and academia, growing public-private initiatives in the field of immunology and immuno-oncology research, and the rising incidence and prevalence of chronic diseases. Based on end user, the cell analysis market is segmented into hospitals & diagnostic laboratories, research institutes, pharmaceutical & biotechnology companies and CROs, cell culture collection repositories, and other end users. The pharmaceutical & biotechnology companies and CROs segment is expected to register the highest CAGR during the forecast period. These facilities use cell analysis instruments and consumables during various stages of drug discovery, drug research and development, pharmacokinetics, toxicology, and clinical studies. Growing regulatory approvals for cell culture-based vaccines, increasing pharmaceutical R&D expenditure, and commercial expansion of various pharmaceutical companies are driving the growth of this end-user segment. Regional Analysis: - By region, the cell analysis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest market share, followed by Europe. Factors such as the presence of a favorable business environment, growing government support through funds and grants, growing number of research activities, rising number of drug discovery initiatives by pharmaceutical & biotechnology companies in the US, and the strong presence of key players in this region are driving the growth of the cell analysis market in North America. Request for Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=157543946 Top Key Players:- The prominent players operating in the cell analysis market are Danaher Corporation (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), GE Healthcare (US), Agilent Technologies, Inc. (US), Olympus Corporation (Japan), PerkinElmer, Inc. (US), Promega Corporation (US), Tecan Group (Switzerland), Miltenyi Biotec (Germany), Carl Zeiss (Germany), Bio-Rad Laboratories Inc (US), and Sysmex Corporation (Japan). What are the regional growth trends and the largest revenue-generating regions INAAT market?6/16/2021 Factors such as the rising prevalence of infectious diseases and the introduction of newer pathogens, the need for prompt diagnosis, the increasing number of blood transfusions and donations, and the cost-benefits of INAAT are the key factors driving the market growth.
The Isothermal Nucleic Acid Amplification Technology/INAAT Market is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11.0% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=839 Market Segmentations:- Based on the product, the INAAT market is segmented into assay, kits, and reagents, and systems. Assay, kits, and reagents segment are expected to account for the largest share of the INAAT industry in 2019, Based on the type, the global market is divided into TMA, LAMP, SDA, HAD, NASBA, and other technologies. Based on application, the INAAT market is segmented into infectious disease diagnosis, blood screening, and other applications such as cancer diagnosis, cancer research, and laboratory research, which encompass cDNA preparation, whole-genome amplification (WGA), single-nucleotide polymorphism (SNP), and mutation analysis. Based on the end user, the market is divided into hospitals, reference laboratories, academic and research institutes, and other end users. Recent Developments:
Regional Analysis:- In 2019, North America is expected to account for the largest share of the global INAAT market, followed by Europe. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=839 Top Key Players:- The major companies in the global INAAT market include Grifols S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories, Inc. (US), Becton, Dickinson & Company (US), and Meridian Bioscience (US). The growth of this market is mainly driven by the growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of organs-on-chips, technological advancements and products launches, growing number of partnerships and collaborations between pharmaceutical companies and organs-on-chips manufacturers, and growing need for early detection of drug toxicity to minimize financial losses due to late stage drug failure.
The Organs-on-chips Market is expected to reach USD 45.6 million by 2022 from USD 9.6 million in 2017, at a CAGR of 36.6%. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144117291 Market Segmentation: - Based on type, the organs-on-chips market is segmented into liver, lung, heart, kidney, and other organs-on-chips. In 2017, the accessories segment is expected to account for the largest share of the organs-on-chips market. The large share of this segment can be attributed to the simplicity of this model and the ability of on-chip hepatic tissues to maintain metabolic activity and phenotype similar to the in vivo environment. Based on application, the organs-on-chips market is segmented into physiological model development, drug discovery, and toxicology research. The drug discovery segment is expected to register the highest CAGR during the forecast period. The increasing focus on drug discovery, rising need for more predictive in vitro tools for drug development among pharmaceutical companies, and growing preference for alternatives to conventional cell culture and animal models are some of the factors that are driving the growth of the drug discovery segment. Key Market Drivers :- 1 Growing Focus on Developing Alternatives for Animal Testing Models 2 Significant Increase in Research Funding and Venture Capital Investments for the Development of Organs-on-Chips 3 Technological Advancements and New Products Launches 4 Growing Number of Partnerships and Collaborations Between Pharmaceutical Companies and Organs-on-Chips Manufacturers 5 Growing Need for Early Detection of Drug Toxicity to Minimize Financial Losses Due to Late Stage Drug Failure 6 Growing Initiatives to Increase Awareness About Organs-on-Chips Technologies Regional Analysis: - In 2017, North America is expected to dominate the market followed by Europe. The large share of this geographical segment is attributed to factors such as availability of new and advanced organs-on-chips in the market. Request for Sample Pages - https://www.marketsandmarkets.com/requestsampleNew.asp?id=144117291 Top key Players:- The organs-on-chips market is emerging and high growth potential market with the presence of several small players and startups firms. Some of the players in the organs-on-chips market include Emulate (US), CN Bio (UK), TissUse (Germany), Mimetas (Netherlands), InSphero (Switzerland), Ascendance Bio (US), Kirkstall (UK), HUREL (HUREL) (US), SynVivo (US), AxoSim (US), and Nortis (US). |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |